FFC#17/2014

TRPA1 channels as novel molecular targets for anti-inflammatory therapies in CF lung

FFC#17/2014

TRPA1 channels as novel molecular targets for anti-inflammatory therapies in CF lung

PRINCIPAL INVESTIGATOR

Giulio Cabrini (Laboratorio di Patologia Molecolare, Dip. di Patologia e Diagnostica, Università di Verona)

Partner

Romina Nassini (Dip. di Scienze Sanitarie, Unità di Farmacologia Clinica e Oncologica, Università di Firenze)

RESEARCHERS

17

CATEGORY

AREA 4 Lung inflammation

DURATION

2 years

GOAL

€ 50.000

RESULTS

TRPA1 channels are expressed In the CF epithelium. Inhibition of TRPA1 expression results in a relevant reduction of several cytokines, including IL-8 and the proinflammatory cytokines Il-1beta and TNF-alfa. TRPA1 channels are a relevant part of the pro-inflammatory signalling regulating CF lung inflammation. The results provide the rationale to test the pharmacological inhibitors of TRPA1 channels, in order to intervene in synergy with other drugs in the cure of the lung pathology of CF patients, with the perspective of drug repositioning to cure the CF lung disease.

OTHER RESULTS

FFC #3/2024

Two molecules are effective in activating Heat Shock Proteins and enhancing the action of CFTR correctors with the F508del mutation in vitro.

FFC#5/2024

Some peptide nucleic acids (PNAs) re-sensitise Pseudomonas aeruginosa to the antibiotic meropenem in vitro and reduce its virulence.

FFC#1/2023

Tezacaftor, one of the components of Kaftrio, induces an accumulation of dihydroceramides both in vitro and in vivo in animal models